PureTech Reports Positive Topline Data from Phase 1b Trial of LYT-200 in Relapsed/Refractory (R/R) High-Risk (HR) Myelodysplastic Syndrome (MDS) and R/R Acute Myeloid Leukemia (AML)

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/24/2026

1. QCOM
2. FDX
3. CBRS
4. USO
5. SPY
6. MU
7. KBH
8. HON
9. HTZ
10. JPM

Go back to PureTech Reports Positive Topline Data from Phase 1b Trial of LYT-200 in Relapsed/Refractory (R/R) High-Risk (HR) Myelodysplastic Syndrome (MDS) and R/R Acute Myeloid Leukemia (AML)
(NASDAQ: PRTC) Delayed: 17.42 --0 (-0%)
Previous Close $17.42    52 Week High $ 
Open $17.42    52 Week Low $ 
Day High $17.42    P/E N/A 
Day Low $17.42    EPS $ 
Volume 3,896       

(NASDAQ: PRTC) Delayed: 17.42 --0 (-0%)
Previous Close $17.42    52 Week High $ 
Open $17.42    52 Week Low $ 
Day High $17.42    P/E N/A 
Day Low $17.42    EPS $ 
Volume 3,896